Considerations for producing mRNA vaccines for clinical trials

6Citations
Citations of this article
30Readers
Mendeley users who have this article in their library.
Get full text

Abstract

The approval of clinical trials by the competent authorities requires comprehensive quality documentation on the new drug to be used on the clinical trial participant. In the EU quality data is summarized as Investigational Medicinal Product Dossier (IMPD), in the USA as Investigational New Drug (IND) Application. For that, several preconditions concerning production, quality control, and assurance have to be fulfilled. Here, specific requirements related to mRNA vaccines are addressed on the basis of European standards.

Cite

CITATION STYLE

APA

Schmid, A. (2017). Considerations for producing mRNA vaccines for clinical trials. In Methods in Molecular Biology (Vol. 1499, pp. 237–251). Humana Press Inc. https://doi.org/10.1007/978-1-4939-6481-9_15

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free